Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Novartis Shutters Antibiotic Firm Protez

by Lisa M. Jarvis
September 27, 2010 | A version of this story appeared in Volume 88, Issue 39

Just two years after acquiring Protez Pharmaceuticals, Novartis has shuttered the biotech firm and stopped developing its broad-spectrum antibiotic candidate, PTZ601. A Novartis official says PTZ601, a carbapenem aimed at hospital-acquired infections, was abandoned because of a higher than anticipated rate of rashes in patients given the compound in a Phase II trial. “Due to the high rate of rash adverse events, the benefit of this compound was considered significantly diminished,” the official says. Novartis paid $100 million up front for Protez and agreed to hand over up to $300 million more in milestone payments.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.